Patents by Inventor Robin Edwin Buckingham

Robin Edwin Buckingham has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20040266833
    Abstract: A use of certain insulin sensitiser or a PPAR&ggr; agonist such as a compound of formula (I) or a tautomeric form thereof and/or a pharmaceutically acceptable salt thereof, and/or a pharmaceutically acceptable solvate thereof, wherein: A1 represents a substituted or unsubstituted aromatic heterocyclyl group; R1 represents a hydrogen atom, an alkyl group, an acyl group, an aralkyl group, wherein the aryl moiety may be substituted or unsubstituted, or a substituted or unsubstituted aryl group; R2 and R3 each represent hydrogen, or R2 and R3 together represent a bond; A2 represents a benzene ring having in total up to five substituents; and n represents an integer in the range of from 2 to 6, for the manufacture of a medicament for treatment and/or prophylaxis of diseases associated with loss of bone mass, such as osteoporosis and related osteopenic diseases, Paget's disease, hyperparathyroidism and related diseases.
    Type: Application
    Filed: November 18, 2003
    Publication date: December 30, 2004
    Inventor: Robin Edwin Buckingham
  • Publication number: 20040254229
    Abstract: A method for reducing or preventing apoptosis of differentiated cells selected from the list consisting of cardiac myocytes, pancreatic beta cells, endothelial cells and neuronal cells in the human or non-human mammal, which method comprises administration, including acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: March 10, 2004
    Publication date: December 16, 2004
    Applicant: SmithKline Beecham p.l.c. and SmithKline Beecham Laboratoires Pharmaceutiques
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Publication number: 20040192737
    Abstract: A method for the treatment of hyperglycaemia wherein plasma glucose levels in the range of from >126 mg/dl to 140 mg/dl, which method comprises administering an effective nontoxic and pharmaceutically acceptable amount of an insulin sensitiser, to a mammal in need thereof.
    Type: Application
    Filed: April 13, 2004
    Publication date: September 30, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robin Edwin Buckingham, Stephen Alistair Smith
  • Publication number: 20040176373
    Abstract: A method for the treatment of diabetes mellitus, especially Type II diabetes and the cardiac conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitizer, such as Compound (I), and an agent used in the treatment of the cardiac conditions associated with diabetes mellitus.
    Type: Application
    Filed: March 18, 2004
    Publication date: September 9, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Robin Edwin Buckingham
  • Publication number: 20040176420
    Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a sub-maximal amount of an insulin secretagogue, to a mammal in need thereof; and a pharmaceutical composition for use in such method.
    Type: Application
    Filed: March 15, 2004
    Publication date: September 9, 2004
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robin Edwin Buckingham, Stephen Alistair Smith
  • Publication number: 20040122060
    Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitizer, an insulin secretagogue and a biguanide antihyperglycaemic agent, to a mammal in need thereof; and composition for use in such method.
    Type: Application
    Filed: December 8, 2003
    Publication date: June 24, 2004
    Applicant: SmithKline Beecham p.I.c.
    Inventors: Robin Edwin Buckingham, Stephen Alistair Smith
  • Publication number: 20040110800
    Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: December 2, 2003
    Publication date: June 10, 2004
    Applicant: SmithKline Beecham p.l.c. & SmithKline Beecham Laboratoires Pharmaceutiques
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Patent number: 6699889
    Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Grant
    Filed: June 12, 2003
    Date of Patent: March 2, 2004
    Assignees: SmithKline Beecham p.l.c., SmithKline Beecham Laboratoires Pharmaceutiques
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Publication number: 20030216455
    Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: June 12, 2003
    Publication date: November 20, 2003
    Applicant: SmithKline Beecham plc & SmithKline Beecham Laboratoires Pharmaceutiques
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Patent number: 6613785
    Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Grant
    Filed: January 21, 2003
    Date of Patent: September 2, 2003
    Assignees: Smithkline Beecham plc, Glaxosmithkline Laboratoires Pharmaceutiques
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Publication number: 20030125358
    Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof
    Type: Application
    Filed: February 5, 2003
    Publication date: July 3, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robin Edwin Buckingham, Michael Urquhart
  • Publication number: 20030109554
    Abstract: A method for reducing post-ischaemic injury of the heart and/or improving the functional recovery of the heart following myocardial ischaemia which method comprises administration of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: January 21, 2003
    Publication date: June 12, 2003
    Applicant: SmithKline Beecham plc
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Publication number: 20030109552
    Abstract: A method for the treatment and/or prophylaxis of renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease, and microalbuminuria which method comprises the administration of an effective, non-toxic amount of an insulin sensitiser to a human or non-human mammal in need thereof.
    Type: Application
    Filed: December 3, 2002
    Publication date: June 12, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Robin Edwin Buckingham
  • Publication number: 20030109561
    Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a sub-maximal amount of an insulin secretagogue, to a mammal in need thereof; and a pharmaceutical composition for use in such method.
    Type: Application
    Filed: January 17, 2003
    Publication date: June 12, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robin Edwin Buckingham, Stephen Alistair Smith
  • Publication number: 20030092750
    Abstract: A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, an insulin secretagogueand an alpha glucosidase inhibitor antihyperglycaemic agent, to a mammal in need thereof; and composition for use in such method.
    Type: Application
    Filed: December 18, 2002
    Publication date: May 15, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robin Edwin Buckingham, Stephen Alistair Smith
  • Publication number: 20030069282
    Abstract: A method for reducing or preventing apoptosis of differentiated cells selected from the list consisting of cardiac myocytes, pancreatic beta cells, endothelial cells and neuronal cells in the human or non-human mammal, which method comprises administration, including acute administration, of an effective, non-toxic amount of a glucose uptake enhancer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: November 8, 2002
    Publication date: April 10, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Antoine Michel Alain Bril, Robin Edwin Buckingham, Nassirah Khandoudi
  • Publication number: 20030069283
    Abstract: A method for the treatment of hyperglycaemia wherein plasma glucose levels are in the range of elevated normal to ≦126 mg/dl, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, to a mammal in need thereof.
    Type: Application
    Filed: December 6, 2002
    Publication date: April 10, 2003
    Applicant: SmithKline Beecham p.l.c.
    Inventors: Robin Edwin Buckingham, Stephen Alistair Smith
  • Publication number: 20030060489
    Abstract: A method for the treatment of diabetes mellitus, especially Type II diabetes and the cardiac conditions associated with diabetes mellitus in a mammal such as a human, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitizer, such as Compound (I), and an agent used in the treatment of the cardiac conditions associated with diabetes mellitus.
    Type: Application
    Filed: October 4, 2002
    Publication date: March 27, 2003
    Inventor: Robin Edwin Buckingham
  • Publication number: 20020156106
    Abstract: A method of treatment and/or prophylaxis of renal diseases including diabetic nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease, and micoralbuminuria which comprises the administration of an effective, non-toxic amount of an insulin sensitizer to a human or non-human mammal in need thereof.
    Type: Application
    Filed: April 22, 2002
    Publication date: October 24, 2002
    Applicant: SmithKline Beecham p.l.c.
    Inventor: Robin Edwin Buckingham
  • Publication number: 20020137773
    Abstract: A method for the treatment of hyperglycaemia wherein plasma glucose levels in the range from >126 mg/dl to 140 mg/dl, which method comprises administering an effective nontoxic and pharmaceutically acceptable amount of an insulin sensitizer, to a mammal in need thereof.
    Type: Application
    Filed: May 24, 2002
    Publication date: September 26, 2002
    Applicant: SmithKline Beecham p.1.c.
    Inventors: Robin Edwin Buckingham, Stephen Alistair Smith